Amplification and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/ FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.
Introduction
Prostate and bladder cancer represent major causes of morbidity and mortality in Europe and North America. For each of these cancers, there are problems relating to the management of the disease. For example, in prostate cancer, there is a significant problem of overtreating early disease and whereas some early cancers progress rapidly, many cancers remain dormant for many years or even decades. New markers are required to predict the behaviour of early disease so that men with indolent cancer can be spared aggressive treatments that are associated with high risk of side effects such as impotence and incontinence. For bladder cancer, most cases (70-80%) are early papillary tumours (pTa or pT1) that have a high rate of papillary recurrence but a low rate of progression (10-20%) to advanced disease. It is, however, not possible to predict in advance which 10-20% of the cases will progress. A better understanding of the mechanism of prostate and bladder cancer development may help address these problems, and the identification of new genes underpinning the development of these cancers, therefore, remains a priority.
Screening of bladder and prostate cancers by comparative genomic hybridization (CGH) onto metaphase chromosomes has identified many regions of genetic gain and loss that may represent the position of novel oncogenes and suppressor genes for both of these cancers (Knowles, 2001; Karan et al., 2003) . Gain and amplification at 6p22 has frequently been reported as a recurrent abnormality in human bladder cancer (Hovey et al., 1998; Koo et al., 1999; Terracciano et al., 1999; Simon et al., 2000) . The presence of this amplification was shown to correlate with tumour grade Prat et al., 2001) and, in high-grade cancers, with tumour cell proliferation rate (Tomovska et al., 2001) . Initial mapping studies indicated that the 6p22 amplicon spanned the SOX4, PRL and E2F3 genes (Bruch et al., 2000; Veltman et al., 2003) and in CGH studies onto cDNA microarrays, we found that only two genes from this region, E2F3 and CDKAL1/FLJ20342 (hereafter called CDKAL1), were consistently amplified in bladder cancers (Feber et al., 2004) . Amplification of E2F3 was accompanied by overexpression of the mRNA transcripts and E2F3 protein. Immunohistochemical analyses of the E2F3 protein levels established that one-third of primary transition cell carcinomas of the bladder overexpressed nuclear E2F3 protein, with the proportion of tumour containing nuclear E2F3 increasing with tumour stage and grade. When considered together with the established role of E2F3 in controlling cell cycle progression, we proposed that E2F3 represented the target gene within the 6p22 amplicon in human bladder cancer (Feber et al., 2004) . Oeggerli et al. (2004) reported similar results, and on the basis of parallel analyses of E2F3 protein and the proliferation marker Ki67 suggested that E2F3 overexpression may provide a growth advantage to tumour cells by activating cellular proliferation in a subset of bladder cancers. In comparison, Hurst et al. (2004) examined amplification of expression levels of the same genes within the 6p22 amplicon, but concluded that the CDKAL1 gene immediately adjacent to E2F3, rather than E2F3 itself, showed the clearest amplicon-related expression in tumour cell lines. In their study, CDKAL1 was therefore proposed as a putative bladder cancer oncogene.
High-level expression of nuclear E2F3 is also found in around two-thirds of human prostate cancer and in multivariate analysis E2F3 expression is an independent factor predicting worse overall and cause-specific survival (Foster et al., 2004) . For both bladder and prostate cancer, we have proposed a model for cancer development in which overexpression of E2F3 cooperates with removal of the retinoblastoma tumour suppressor protein (pRB) suppressor control at the G1/S transition in the cell cycle (Feber et al., 2004; Foster et al., 2004) . In addition to removal of RB1 itself, many of the genetic changes found in bladder cancer may indirectly lead to pRB inactivity, for example, elevating cyclin D1, removing the cyclin-dependent kinase (CDK) inhibitor p16, mutating the TP53 gene or amplifying and overexpressing MDM2 (Knowles, 2001) . For prostate cancer, it has been proposed that downregulation of pRB represents an early event in prostate cancer development and loss of pRB is a prognostic marker for cancer development (Theodorescu et al., 1997) . Loss of expression of p16 an upstream regulator of pRB is also of prognostic significance in locally advanced disease (Chakravarti et al., 2003) .
The objectives of the present study were to obtain direct evidence that the level of expression of E2F3 can control cellular proliferation rates in human bladder and prostate cancer cells and to test the hypothesis for cancer development that involves cooperation between E2F3 overexpression and pRB removal. We have also used expression analyses onto cDNA microarrays to identify the downstream targets of E2F3 overexpression.
Results

Knockdown of mRNA in bladder cancer cells containing amplification and overexpression of E2F3 and CDKAL1
In a previous study, we reported amplification of both E2F3 and CDKAL1 genes in the TCCSUP, 5637 and HT1376 bladder cancer cell lines (Feber et al., 2004) . We also demonstrated that in all these three cell lines, amplification of the E2F3 gene was accompanied by E2F3 mRNA overexpression and high-level expression of the E2F3 proteins. In Northern blot analyses, we first confirmed the observation of Hurst et al. (2004) that the amplification of the CDKAL1 gene in these cell lines is also accompanied by mRNA overexpression (Figure 1a) . The bladder cancer cell line 5637 that exhibits amplification and overexpression of both E2F3 (Figure 2 ) and CDKAL1 was then chosen for small interfering RNA (siRNA)-mediated knockdown studies. In initial studies, 5637 cells were treated with siRNA specifically targeting E2F3 (E2F3si1, 2 and 3) or CDKAL1 gene expression (CDKAL1si1, 2 and 3) for 24 h before assessing expression levels of E2F3 protein ( Figure 3a ) and CDKAL1 mRNA, respectively (Figure 1b) . Control cultures were treated with the corresponding scrambled siRNAs. CDKAL1si1 removed expression of CDKAL1 mRNA by at least 95% compared to its scrambled control as determined by Northern blotting. E2F3si1 and E2F3si3 were most effective at reducing expression of the E2F3 protein, as judged by Western blotting. To further assess the effectiveness of E2F3 knockdown, fluorescent immunohistochemical staining for E2F3 was performed on intact 5637 bladder cells that had been incubated for 24 h with E2F3si3 (Figure 3b and c) . These studies demonstrate a reduction of nuclear E2F3 staining in E2F3si3-treated cells that did not occur in cells treated with corresponding scrambled siRNA.
Bromodeoxyuridine (BrdU) incorporation was used as a marker for cellular proliferation rate to assess the effect of E2F3 and CDKAL1 knockdown (Dolbeare, 1996) . BrdU is incorporated as a thymidine analogue into newly synthesized DNA and allows assessment of the proportion of cells cycling through S phase during the period of BrdU treatment. BrdU incorporation was assessed by direct examination through an immunofluorescence microscope following treatment with (b) CDKAL1 expression following treatment with CDKAL1 siRNAs (si1, si2 and si3) or the corresponding scrambled controls (sc1, sc2 and sc3). There is no statistically significant change in E2F3 levels after this treatment, as determined by Taqman. GAPDH expression is used as a loading control.
siRNAs for up to 72 h. Treatment of 5637 cells with E2F3si3 resulted in a reduction in proliferation rate (as measured by the proportion of cells incorporating BrdU) from around 30 to 7% after 72 h (w 2 for trend, P ¼ 0.0026) (Figure 4a ), whereas the corresponding scrambled siRNA had no effect. Similar experiments performed with CDKAL1si1 failed to significantly alter the proliferation rate (Figure 4b ).
To confirm and extend these observations, BrdU incorporation was also assessed by fluorescence-activated cell sorting (FACS). The BrdU incorporation for 5637 at 72 h was reduced from 22% of cells to 5% with E2F3si3 (Student's t-test, P ¼ 0.0002; Figure 5 ). To exclude the possibility that this biological outcome resulted from off target effects on other cellular genes, the studies were repeated using E2F3si1. A significant reduction of BrdU incorporation from 22 to 15% following treatment with E2F3si1 (Student's t-test, P ¼ 0.0002) was observed. This lower reduction in BrdU incorporation reflected the poorer knockdown of E2F3 protein observed using E2F3si1 compared to E2F3si3 (60 vs 90%). Treatment of cells with CDKAL1si1 again failed to alter the extent of BrdU incorporation. In order to confirm that the decreased BrdU incorporation is indeed a reflection of decreased cell proliferation, we performed a growth assay. This showed that the number of cells was significantly reduced (76%) following treatment with E2F3si3 (Student's t-test, Pp0.0001) compared to E2F3sc3 ( Figure 5 ). We have also verified that the cells are not undergoing apoptosis (results not shown).
Overexpression of E2F3 enhances cellular proliferation rate in DU145 prostate cancer cells The E2F3 gene encodes two proteins, E2F3a and E2F3b, through the use of alternative 5 0 -coding exons ( Leone et al., 2000) . We wished to investigate whether ectopic expression of E2F3a, a transcriptional activator, could modulate cellular proliferation rate, as measured by the extent of BrdU incorporation. The prostate cancer cell line DU145 was chosen because it had only a low level of endogenous E2F3 and is reported to have a mutated RB1 allele (Bookstein et al., 1990) , consistent with the Western blot analyses showing lack of pRB protein expression (Figure 2 ). Knockdown of E2F3 in DU145 failed to alter the BrdU incorporation, consistent with the view that the low levels of E2F3 present in this line is not driving cellular proliferation on its own. In contrast, when E2F3a was ectopically expressed, a significant enhancement in the BrdU incorporation was observed (13.8-22.1%, Student's t-test, P ¼ 0.038; Figure 6a ). These experiments indicate that increasing expression of E2F3a in cells lacking active pRB can enhance the rate of cellular proliferation.
Cooperation between E2F3 overexpression and RB1 removal in prostate cancer cells The prostate cancer cell line PC3 was used to establish whether cooperation between pRB removal and E2F3a overexpression can modulate the rate of BrdU incorporation. This cell line was chosen because it has both a low level of E2F3 expression and expresses wild-type pRB protein ( Figure 2 and http://www.sanger.ac.uk/ genetics/CGP/CellLines/). Ectopic expression of E2F3a alone failed to induce a significant increase in the extent of BrdU incorporation ( Figure 6b ). This observation is consistent with the view that the action of E2F3a is inhibited by pRB present in this cell line. To test this idea, siRNA technology was used to knock down pRB expression in PC3 cells. Interestingly, transient knockdown of pRB alone resulted in inhibition of the BrdU incorporation, an observation that was also found in similar studies in the prostate cell line 22Rv1 (results not shown). When E2F3a was ectopically expressed in cells in which pRB had been knocked down, a significant enhancement in BrdU incorporation (from 17.8 to 33.3%, Student's t-test, P ¼ 0.0036) was observed. Taken together, these observations support the idea that removal of pRB and overexpression of E2F3a cooperate to enhance the rate of cellular proliferation.
Identification of downstream target genes modulated by E2F3
We wished to identify genes modulated by E2F3 amplification and overexpression in human bladder cells. To achieve this, E2F3 expression was knocked down using E2F3si3 and the expression pattern studied using microarrays containing 32 000 cDNAs. Cy5-labelled cDNA from E2F3si3-treated 5637 cells and Cy3-labelled cDNA treated with its scrambled siRNA control, were co-hybridized onto the cDNA microarray. In our initial analyses of the data, the Cy5:Cy3 ratio had to exceed twofold in two independent experiments to qualify that gene as differentially expressed. Using these criteria, 54 genes were differentially underexpressed following E2F3 knockdown, suggesting that they are potential E2F3a targets, whereas 30 genes were differentially overexpressed (Table 1) . To investigate whether the differentially expressed genes are potentially primary targets for E2F3, the promoter regions of these genes were searched for E2F3-binding sites. Within the promoter regions identified, E2F3-binding sites were found in 86% of the genes downregulated by E2F3 depletion, but interestingly also in 81% of the upregulated genes, suggesting that both classes of genes may be E2F3 transcriptional targets. Ingenuity pathway analysis software was used to identify the biological networks and pathways in which the differentially expressed genes are involved. These analyses indicated that E2F3-regulated genes are involved in a variety of networks and pathways, including cellular proliferation, cell death, cellular movement, DNA replication, recombination and repair. The highest scoring network involved in cell cycle regulation and cancer is shown in Supplementary Figure 1 . 
Discussion
There is substantial evidence supporting the importance of E2F3 in controlling cell cycle progression and proliferation in neoplastic and non-neoplastic cells. Mouse embryo fibroblasts (MEFs) with a defect in the E2F3 gene (E2F3À/À) have a proliferative and cell cycle defect when compared to their wild-type counterparts and at a critical threshold level, E2F3-controlled genes appear to determine the time of the G1/S transition (Leone et al., 1998; Humbert et al., 2000; Wu et al., 2001) . Additionally, microinjection of E2F3 antibodies into the MEFs impairs entry into S phase (Leone et al., 1998) . E2F3a overexpressed under the keratin 5 promoter in transgenic mice has been found to have weak carcinogenic activity and to significantly enhance the production of chemically induced skin cancers (Paulson et al., 2006) . In contrast, in transgenic mice expressing inducible E2F3a in the pituitary gland, the deregulation of E2F activity resulted in hyperplasia, but did not lead to tumour formation (Lazzerini Denchi et al., 2005) . In bladder cancer cells, which contain amplification and overexpress E2F3 at a high level, we found that reduction of E2F3 protein using siRNA technology was accompanied by a reduction in BrdU incorporation and cellular proliferation. This is consistent with the observation that the presence of the 6p22 amplicon correlates with tumour cell proliferation rate (Tomovska et al., 2001) and with the observed correlation between expression of E2F3 and the Ki67 proliferation marker (Oeggerli et al., 2004) . In contrast, we failed to find evidence to support the view that CDKAL1 represents the bladder cancer oncogene within the 6p22 amplicon (Hurst et al., 2004) : knocking down expression of this gene did not alter the BrdU incorporation. The possibility that CDKAL1, which is consistently overexpressed within the 6p22 amplicon, makes some other contribution to tumour development in bladder cancer cells cannot be excluded. Indeed, it is common to find that overexpression of more than one gene within an amplicon contributes to cancer development (Schwab, 1998) .
In a majority of bladder and prostate cancers, at least one of the following alterations is found: overexpression of cyclins, activation of CDK, inactivation of CDK inhibitors or loss of pRB expression. These events all result in inactivation of the pRB tumour suppressor, which gives growth advantage and allows bypass of cellular senescence pathways (Malumbres and Barbacid, 2001) , and are believed to represent an early event in tumour development (Phillips et al., 1994) . Interestingly, the deletion of one RB1 allele in mouse prostate gives rise to focal prostate hyperplasia, but these lesions do (RbSi3 þ pE2F3a) . The standard errors of the mean from three independent experiments is shown. In Western blotting, GAPDH was used as a loading control. (Maddison et al., 2004) . pRB plays a critical role in cell cycle progression by binding and inhibiting E2Fs, and hence preventing S-phase entry, until it is phosphorylated by CDKs. It is our hypothesis that pRB inactivation and E2F3 overexpression can cooperate in human tumour formation. In transgenic mouse studies, E2F3 has been shown to contribute to the ectopic proliferation of neuronal cells and lense fibre cells in RbÀ/À null mice (Saavedra et al., 2002) . The results presented in this study also support this hypothesis. Ectopic overexpression of E2F3a in DU145 cells that contain a mutated pRB enhances the extent of BrdU incorporation. In PC3 cells containing wild-type pRB, however, ectopic E2F3a expression enhanced BrdU incorporation only when levels of pRB had been substantially reduced by siRNA knockdown. We have identified genes controlled by E2F3 expression in bladder cancer cells containing amplification and overexpression of this gene by expression cDNA microarray analyses on 5637 following E2F3 knockdown.
Role of E2F3 expression in human bladder and prostate cancer cells AY Olsson et al
Among the differentially expressed genes were known E2F3 targets such as Cyclin A and CDC2 (Humbert et al., 2000) , but also many novel potential targets including Polo-like kinase 1 (PLK1), Caveolin-2, pituitary tumour transforming gene 1 (PTTG1), MAD2L1 and thrombospondin-1 (THBS1). PLK1 overexpression has been observed in bladder and prostate tumours and has been shown to correlate with poor prognosis, and siRNA targeting PLK1 effectively prevents growth of cancer cells (Weichert et al., 2004; Nogawa et al., 2005) . The expression of Caveolin-2 is positively correlated with tumour grade and squamous features of urothelial carcinoma (Fong et al., 2003) and it forms hetero-oligomeric complexes with Caveolin-1, that are correlated to disease progression and metastasis in human prostate cancer (Thompson et al., 1999) . PTTG1 is a novel oncogene that may serve as a prognostic marker for tumour invasiveness and metastasis (Ramaswamy et al., 2003) , and MAD2L1 has been associated with lymph node metastasis of several cancer types (Bidus et al., 2006) . THBS1 was the gene most correlated with E2F3 knockdown; it has been linked to Expression cDNA microarray on RNA isolated from 5637 bladder cancer cells treated with E2F3si1 compared to cells treated with the corresponding scrambled siRNA. To qualify as differentially expressed, the change had to exceed 2.0-fold in at least two experiments. The mean ratio of three experiments is shown.
b To identify E2F3-binding sites, promoter regions was identified using Dragon Promoter Finder in Transplorer (Biobase GmbH, Wolfenbu¨ttel, Germany) in the 5000 bp upstream region and the first exon of each of the differentially expressed genes. These sequences were searched for E2F-binding sites by a Matrix Search using E2F M00803 and E2F M00050 that are E2F3 specific, at 95% stringency. + indicates that an E2F3-binding site has been found, À that it was nor found in the promoter region searched, and N/A, the promoter region could not be identified.
antiangiogenesis and is upregulated in androgenindependent prostate cancer compared to androgendependent disease (Best et al., 2005) . All of the above-mentioned genes were found to contain E2F3-binding sites in their promoters, as did 89% of all the genes found to be positively regulated by E2F3 in this study, suggesting that they could be primary E2F3 targets.
Our approach to identify E2F3 targets involved measuring gene expression following the knockdown of E2F3 expression using siRNA technology in 5637 bladder cancer cell line with mutated pRB. In contrast, other studies have attempted to identify genes modulated by E2F3a through the ectopic expression of this gene. When E2F3a was ectopically expressed in quiescent mouse fibroblasts (Black et al., 2005) , only four of the genes found to be differentially expressed (PCNA, PTMA, MAD2L1 and Rrm2) were common to our lists. When E2F3a was overexpressed in primary mammary epithelial cells (Bild et al., 2006) , only PCNA was common to our lists. These differences might reflect the different approaches used in these studies and that key genes controlled by E2F3 may depend on its cellular context.
In conclusion, we have shown that E2F3 affects the BrdU incorporation, as a measurement of proliferation rate, in bladder and prostate cancer cells. Furthermore, the expression analysis suggests that E2F3 expression affects other pathways that could also potentially contribute to tumour development and progressions and this merits further investigations.
Materials and methods
siRNA and expression vector design siRNA oligonucleotides (21 nt long) were synthesized, annealed and purified by Dharmacon (Lafayette, CO, USA). The siRNA probes were designed to specifically target sequences encoding either the E2F3 (sequences common to the a and b isoforms were chosen) or the CDKAL1 open reading frame according to the rules suggested by Elbashir et al. (2002) (Supplementary Table 1 ). Scrambled controls were produced by scrambling the corresponding target siRNA sequences. All siRNA sequences were subjected to BLAST search to confirm the absence of homology to any additional known sequences in the human genome. To produce a construct encoding the E2F3a protein, mRNA isolated from 5637 was reversed transcribed using the SuperscriptIII Kit (Invitrogen, Carlsbad, CA, USA), and the full-length cDNA was amplified using the E2F3-specific primers E2F3F: 5 0 -AAAGAGCAGGAGCGA GAGAT-3 0 and E2F3R: 5 0 -ACCAGAACATCTGTCATG CAGT-3 0 , and Platinum Taq High Fidelity DNA Polymerase (Invitrogen) according to the manufacturer's instructions. The polymerase chain reaction product was cloned into a pCIneo vector (Promega, Madison, WI, USA) and the identity of the insert confirmed by DNA sequencing. The E2F3a insert was found to contain three silent mutations compared to the published sequence Y10479.
Transient transfection of siRNA and expression vector
The human prostate cancer cell lines DU145, PC3, 22Rv1 and LNCaP and the bladder cancer cell lines 5637, T24 and SCaBER were obtained from American Type Culture Collection. They were screened for E2F3 and pRB levels using Western blots, in order to determine the most suitable cell lines for the functional studies of the role of E2F3. The cell lines were then screened with a variety of transfection agents to find cell lines that could be most efficiently transfected with siRNA and expression vectors. Based on these analyses, the cell lines 5637, DU145 and PC3 were selected for our studies. All cell lines were cultured as recommended by the supplier. For transfections, approximately 2 Â 10 5 cells were plated per well of a six-well plate in medium containing 10% fetal calf serum (FCS) and cultured for 24 h to give 40-60% confluence. The siRNA or expression vectors were introduced into the cells by complex formation with Lipofectamine2000 essentially according to the recommendations of the manufacturer (Invitrogen). Briefly, 200 nM of siRNA oligonucleotides or 1 mg of vector construct was mixed with 5 ml of Lipofectamine2000 in 200 ml of serum-free medium. Lipofectamine complexes were allowed to form for 20 min at room temperature after which the samples were diluted in 1.0 ml of serum-free medium and then added dropwise to the plates containing the cells. When cotransfections of expression constructs and siRNA were performed, the separate complex formation was allowed to form and mixed just before addition to the cells. The plates were incubated for 6 h, before 0.5 ml of serum-containing media was added to a final concentration of 10% FCS. The cells were analysed 24-72 h after transfection.
Protein extraction and Western blotting Cells were lysed using MPER (Pierce, Rockford, IL, USA) and proteins extracted according to the manufacturer's instruction. Proteins were electrophoresed under non-reducing conditions on 4-12% Bis-Tris gradient gels (Invitrogen), and transferred to an Immobilon polyvinylidene difluoride membrane (Invitrogen). Immunoblotting was performed using E2F3 (Upstate PG37), pRB (Pharmingen G3-245) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Chemicon, Hampshire, UK, MAB374) antibodies.
RNA extraction and Northern blot
Total RNA was extracted from growing cells using either a cytoplasmic lysis method, according to Wilkinson (1988), or Trizol (Invitrogen) according to the manufacturer's instructions. The Northern blots were carried out using standard methods (Sambrook and Russell, 2001) . A 7 mg portion of total RNA was loaded per lane. The blots were hybridized with probes specific for E2F3 or CDKAL1, derived from IMAGE clones 2163947 and 1241671, respectively, which have been sequenced and confirmed after cloning. GAPDH was used as a loading control, and normal bladder RNA (Clontech, Mountain View, CA, USA) was included for comparison. The probes were labelled with [a-32 P]dCTP using the Bioprime kit (Invitrogen) according to the manufacturer's instruction.
Immunoflorescent histochemistry 5637 cells were stained for E2F3 expression or BrdU using standard methods. Briefly, cells were grown on glass coverslips, and cells to be stained with BrdU were incubated with culture media containing BrdU (Amersham Biosciences, Bucks, UK) at a dilution of 1:10 000 (10 mM) for 1 h. All cells were fixed with 70% ethanol and washed, and the BrdUtreated cells were incubated for 10 min with 2 M HCl. The primary antibodies used were anti-BrdU (Abcam Ltd, Cam, UK) and E2F3 (Upstate PG37) and the secondary, Texas-redconjugated antibody (Molecular Diagnostics, Chicago, IL, USA) and anti-mouse fluorescein-5-isothiocyanate (FITC)-conjugated antibody (Molecular Probes, Eugene, OR, USA).
Vectashield (Vecta Laboratories, Burlingame, CA, USA) containing 4 0 ,6-diamidino-2-phenylindole was used to stop fading of the fluorescent antibody and counterstain the nuclei.
Cell proliferation flow cytometry assay
The cells were incubated with culture media containing BrdU (Amersham Biosciences, Bucks, UK) at a dilution of 1:10 000 (10 mM) for 1 h before trypsinasation and fixation in 70% ethanol. The fixed cells (B4 Â 10 5 ) were incubated in 2 M HCl containing 0.2 mg/ml pepsin for 20 min, and washed twice in phosphate-buffered saline (PBS) before incubation with monoclonal rat anti-BrdU antibody diluted 1:50 in blocking buffer (1% bovine serum albumin, 0.5% Tween 20 in PBS) for 1 h at room temperature. The cells were subsequently washed in PBS and incubated with anti-rat IgG FITC-conjugated antibody at 1:100 for 30 min, washed and stained with propidium iodide. Samples were analysed on a Beckman Coulter Elite ESP (Beckman Coulter, High Wycombe, UK), and bivariate cell cycle analysis was performed with WinMidi2.8 software (Scripps Research Institute, La Jolla, CA, USA).
Growth assay
At 72 h after transfection, 5637 bladder cancer cells were immersed in 10% ice-cold trichloroacetic acid and left for 30 min on ice. The plates were washed three times in water before adding 0.4% sulphorhodamine B (SRB) (SigmaAldrich, Poole, UK) in 1% acetic acid and incubating for 15 min. The unbound SRB are washed off with 1% acetic acid and the SRB solubilized with 10 mM Tris base and the absorbance was measured at 540 nm.
Expression cDNA microarrays
The Amersham first strand cDNA post-labelling kit was used to label 5 mg of total RNA, according to the manufacturer's recommendations. The control samples were labelled with Cy3 and the test samples with Cy5, and hybridized to CRUK Human Whole Genome-wide Array v1.0.0 (30K) cDNA microarray slides (http://www.crukdmf.icr.ac.uk/) coated with poly-L-lysine. The hybridization was carried out in triplicate essentially as described previously (Clark et al., 2002) . Slides were incubated at 651C for 1 h and then transferred to 421C for 72 h. The signals were detected and visualized by GenePix 4000B scanner and software (Axon Instruments, Foster City, CA, USA), and data were filtered for quality by automated spot flagging and manual inspection, and analysed in Genespring (Silicon Genetics, Redwood City, CA, USA), using per spot and per chip intensity-dependent Lowess normalization. The gene list of differentially expressed genes was uploaded into the Ingenuity pathway analysis (Ingenuity, Mountain View, CA, USA). A score was computed for each network according to the fit of the original set of significant genes. This score reflects the negative logarithm of the P-value, which indicates the likelihood of the focus genes in a network being found together as a result of random chance. To identify E2F3-binding sites, promoter regions were identified using Dragon Promoter Finder in Transplorer (Biobase GmbH, Wolfenbu¨ttel, Germany) in the 5000 bp upstream region and the first exon of each gene or by literature search. The promoter sequences were then searched for E2F-binding sites by a Matrix Search using E2F M00803 and E2F M00050 that are E2F3 specific, at 95% stringency.
